NIKA PHARMACEUTICALS, INC.
Income Statement
| Line Item | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Gross Margin | — | — | — | — |
| Operating Expenses | ||||
| Research & Development | — | — | — | — |
| SG&A Expense | $35.2K | $64.8K | $33.7K | $14.7K |
| Operating Income | $-95.8K | $-64.8K | $-3.2M | $-14.7K |
| Operating Margin | — | — | — | — |
| Interest Expense | — | — | — | — |
| Pretax Income | $-95.8K | $-64.8K | $-3.2M | $-14.7K |
| Income Tax Expense | — | — | — | — |
| Net Income | $-95.8K | $-64.8K | $-3.2M | $-14.7K |
| Net Margin | — | — | — | — |
| EPS (Basic) | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | 1.02B | 876.1M | 724.0M | 396.1M |
| Shares Outstanding (Diluted) | 1.02B | 876.1M | 724.0M | 396.1M |
| Dividends Per Share | — | — | — | — |